This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock About Interpace Biosciences Stock (NASDAQ:IDXG) 30 days 90 days 365 days Advanced Chart Get Interpace Biosciences alerts:Sign Up Key Stats Today's Range$0.84▼$0.8550-Day Range$4.75▼$10.4052-Week Range$2.57▼$10.42Volume3,060 shsAverage Volume6,816 shsMarket Capitalization$3.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Read More Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDXG Stock News HeadlinesInterpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual MeetingSeptember 15 at 9:15 AM | globenewswire.comSPDI Announces Arcona Share Distribution TimetableSeptember 11, 2025 | tipranks.comWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained to stay alive when systems collapse. In Operation Gold Rush, Jason Hanson reveals how gold and silver saved his life—and how they could protect yours in the next crisis. You’ll learn how to hide gold like a covert operative, secure your 401(k) in physical assets, and prepare for grid failures, economic collapse, or worse.September 16 at 2:00 AM | Advantage Gold (Ad)PDI: 3 Reasons To Run Far Away As PossibleAugust 31, 2025 | seekingalpha.comPDI CEF: Best Time To Sell In 5 YearsAugust 5, 2025 | seekingalpha.comPDI Declares Monthly Dividend with Over 13% YieldAugust 4, 2025 | gurufocus.comPDI: Credit Offers Opportunity In An Expensive MarketJuly 29, 2025 | seekingalpha.comPDI's 13.8% Yield - Despite Coverage Shortfall, CEF Worth ConsideringJuly 29, 2025 | seekingalpha.comSee More Headlines IDXG Stock Analysis - Frequently Asked Questions How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (NASDAQ:IDXG) announced its earnings results on Monday, November, 4th. The business services provider reported $0.31 earnings per share (EPS) for the quarter. The business services provider had revenue of $12.30 million for the quarter. Interpace Biosciences had a net margin of 10.39% and a negative trailing twelve-month return on equity of 8.09%. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX). Company Calendar Last Earnings11/04/2024Today9/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Services Current SymbolNASDAQ:IDXG CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees152Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$800 thousand Net Margins10.39% Pretax Margin10.93% Return on Equity-8.09% Return on Assets37.14% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual Sales$40.21 million Price / Sales0.09 Cash Flow$0.43 per share Price / Cash Flow1.99 Book Value($14.16) per share Price / Book-0.06Miscellaneous Outstanding Shares4,410,000Free Float4,167,000Market Cap$3.75 million OptionableNot Optionable Beta0.76 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:IDXG) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.